Innoviva (INVA) Retained Earnings (2010 - 2026)
Innoviva's (INVA) quarterly Retained Earnings came in at $456.0 million in Q1 2026, up 1042.44% YoY from $39.9 million in Q1 2025, and up 69.27% on a QoQ basis from $269.4 million in Q4 2025.
Innoviva (INVA) Retained Earnings (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Retained Earnings data on file, last reported at $456.0 million in Q1 2026.
- Quarterly Retained Earnings rose 1042.44% year-over-year to $456.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $456.0 million (up 1042.44% YoY) and the FY2025 annual result came in at $269.4 million, up 15089.87% from the prior year.
- Retained Earnings advanced to $456.0 million in Q1 2026, from $269.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $456.0 million in Q1 2026 to a low of -$204.9 million in Q4 2022.
- A 5-year average of -$2.0 million and a median of -$23.3 million in 2024 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 15089.87% in 2025, down 526.53% in 2025.
- Tracing INVA's Retained Earnings over 5 years: stood at -$204.9 million in 2022, then soared by 87.71% to -$25.2 million in 2023, then soared by 92.87% to -$1.8 million in 2024, then soared by 15089.87% to $269.4 million in 2025, then soared by 69.27% to $456.0 million in 2026.
- The last three Retained Earnings figures came in at $456.0 million (Q1 2026), $269.4 million (Q4 2025), and $105.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 372.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 372.54 Mn |
| Mar 31, 2026 | 455.96 Mn |
| Dec 31, 2025 | 269.37 Mn |
| Sep 30, 2025 | 105.22 Mn |
| Jun 30, 2025 | 15.31 Mn |
| Mar 31, 2025 | -48.38 Mn |
| Dec 31, 2024 | -1.80 Mn |
| Sep 30, 2024 | -22.13 Mn |
| Jun 30, 2024 | -23.34 Mn |
| Mar 31, 2024 | 11.34 Mn |
| Dec 31, 2023 | -25.19 Mn |
| Sep 30, 2023 | -86.72 Mn |
| Jun 30, 2023 | -168.77 Mn |
| Mar 31, 2023 | -170.05 Mn |
| Dec 31, 2022 | -204.91 Mn |
| Sep 30, 2022 | -136.60 Mn |
| Dec 31, 2021 | -456.15 Mn |
| Sep 30, 2021 | -466.49 Mn |
| Jun 30, 2021 | -538.93 Mn |
| Mar 31, 2021 | -627.88 Mn |